Video

Dr. Kutikov on Tumor Pathology in Renal Cell Carcinoma

Alexander Kutikov, MD, FACS, attending surgeon, urologic oncology, associate professor, urologic oncology, Fox Chase Cancer Center, discusses the understanding of tumor pathology in renal cell carcinoma.

Alexander Kutikov, MD, FACS, attending surgeon, urologic oncology, associate professor, urologic oncology, Fox Chase Cancer Center, discusses the understanding of tumor pathology in renal cell carcinoma.

Treatment of renal cell carcinoma has been boiled down to calibrating imbalanced risk, Kutikov explains. When consulting a patient who presents a renal mass, it is questionable whether to treat it or to use active surveillance. However, there needs to be a greater understanding of active surveillance and associated risks of that, he adds.

The urologic community is aiming to better understand tumor pathology in renal cell carcinoma, prior to tumor resection, Kutikov says. An example of this would be to better utilize renal biopsies.

<<<

View more from the 2015 AUA Annual Meeting

Related Videos
Funda Meric-Bernstam, MD
Laurence Albigès, MD, PhD
Nirav Shah, MD, MSHP, discusses evaluating zamtocabtagene autoleucel in patients with relapsed/refractory diffuse large B-cell lymphoma.
Bhagirathbhai Dholaria, MBBS
Sairah Ahmed, M.D
Barry W. Goy, MD
Fred Saad, CQ, MD, FRCS, FCAHS, director, Prostate Cancer Research, Montreal Cancer Institute, Centre Hospitalier de l’Université de Montréal; full professor, Department of Surgery, Université de Montréal; uro-oncologist, Urology Department, University of Montreal Health Center
Manmeet Singh Ahluwalia, MD, MBA, FASCO, chief scientific officer, chief, medical oncology, deputy director, Fernandez Family Endowed Chair in Cancer Research, Baptist Health Miami Cancer Institute
Kelly E. McCann, MD, PhD, assistant professor, breast medical oncologist, UCLA
Neeta Somaiah, MD